000			03759nam a22003735i 4500
001			233154
003			ES-VaUE
005			20221220020441.0
007			cr nn 008mamaa
008			100301s1987 xxu| s |||| 0|eng d
020			_a9781603274067
024	7		_a10.1007/978-1-60327-406-7 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
100	1		_aGray, Joe W. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut
245	1	0	_aTechniques in Cell Cycle Analysis _cby Joe W. Gray, Zbigniew Darzynkiewicz.
250			_a1st edition 1987
264		1	_aTotowa, NJ _bHumana Press _c1987
300			_a1 recurso en línea (XVIII, 407 páginas) _b97 ilustraciones
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aBiological Methods
505	0		_aAutoradiographic Techniques for Measurement of the Labeling Index -- Percent Labeled Mitosis Curve Analysis -- Tumor Growth Fraction Estimation, Perturbation, and Prognostication -- In Vitro Assays for Tumors Grown In Vivo -- Flow Cytokinetics -- Solid Tissue Dispersal for Cytokinetic Analyses -- Multivariate Cell Analysis -- Data Analysis in Cell Kinetics Research -- Cytochemical Probes of Cycling and Quiescent Cells Applicable to Flow Cytometry -- Assay of Cell Cycle Kinetics by Multivariate Flow Cytometry Using the Principle of Stathmokinesis -- Flow Cytometric Studies on Intracellular Drug Fluorescence -- Cell Synchrony Techniques.
520			_aQuantification of the proliferative characteristics of normal and malignant cells has been of interest to oncolo­ gists and cancer biologists for almost three decades. This interest stems from (a) the fact that cancer is a disease of uncontrolled proliferation, (b) the finding that many of the commonly used anticancer agents are preferentially toxic to cells that are actively proliferating, and (c) the observa­ tion that significant differences in proliferation characteristics exist between normal and malignant cells. Initially, cell cycle analysis was pursued enthusiastically in the hope of gener­ ating information useful for the development of rational cancer therapy strategies; for example, by allowing identi­ fication of rapidly proliferating tumors against which cell cycle-specific agents could be used with maximum effec­ tiveness and by allowing rational scheduling of cell cyc- specific therapeutic agents to maximize the therapeutic ratio. Unfortunately, several difficulties have prevented realiza­ tion of the early promise of cell cycle analysis: Proliferative patterns of the normal and malignant tissues have been found to be substantially more complex than originally an­ ticipated, and synchronization of human tumors has proved remarkably difficult. Human tumors of the same type have proved highly variable, and the cytokinetic tools available for cell cycle analysis have been labor intensive, as well as somewhat subjective and in many cases inapplicable to humans. However, the potential for substantially improved cancer therapy remains if more accurate cytokinetic infor­ mation about human malignancies and normal tissues can be obtained in a timely fashion.
700	1		_aDarzynkiewicz, Zbigniew. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut
776	0	8	_iPrinted edition: _z9781489941015
776	0	8	_iPrinted edition: _z9781489941008
776	0	8	_iPrinted edition: _z9780896030978
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-1-60327-406-7 _z(usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
988			_aSpringer_Protocols_1987
999			_c233154 _d233154